FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:601-603 February 29, 1996 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

To the Editor: Acute myeloid leukemia (AML) occurs in up to 15 percent of patients treated with cytotoxic drugs, radiation, or both.¹ In the leukemic cells of these patients, losses of chromosome 5, 7, or both are most common; a balanced translocation involving chromosome band 11q23 and the MLL gene is closely associated with prior treatment with drugs that inhibit topoisomerase II.^2,3,4,5,6

The Clinical Investigations Branch of the National Cancer Institute has compiled eight cases of chemotherapy-related AML among the 2548 patients with node-positive breast cancer who were enrolled in Protocol B25 of the National Surgical Adjuvant Breast and Bowel . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.